[Skip navigation] FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Warning Letters and Untitled Letters
to Pharmaceutical Companies
2005

These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office. This page only covers Division of Drug Marketing and Communications and Headquarters Warning Letters.  For District Office Warning Letters see the Main FDA FOI Warning Letters Page.    Some of the letters have been redacted or edited to remove confidential information. Click on the month to view the letters in Adobe Acrobat format.

Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to: Food and Drug Administration, Freedom of Information Staff (HFI-35), 5600 Fishers Lane, Rockville, MD 20857. Instructions for how to submit an FOI request can be found on the FDA FOI Page.

The letters are arranged in chronological order by month.  Click on the month to view the letters in Adobe Acrobat (PDF) format. Go here for further information about Adobe Acrobat and download instructions.

Also see the "Cyber" Letters.

[2008] [2007] [2006] 2005 [2004] [2003] [2002] [2001] [2000] [1999] [1998] [1997]
December 2005
Product/Issue Company/Individual Division Released Posted
Inspection (Warning Letter) IIT Research DSI 12/5/1005 12/20/2005
Clinical Investigation Inspection (Warning Letter) Raymond E. Tidman, M.D. DSI 12/19/2005 1/11/2006
Zevalin (ibritumomab tiuxetan) Biogen Idec Inc. DDMAC 12/15/2005 2/8/2006
November 2005
Product/Issue Company/Individual Division Released Posted
"Barbec Basics Natural Progesterone Cream" (Warning Letter)
PDF or HTML
One Life USA DNDLC 11/9/1005 11/10/2005
"HMS Queen's Progesterone" and "HMS King's Progesterone"   (Warning Letter) PDF or HTML HMS Crown DNDLC 11/9/2005 11/10/2005
Vitrase (hyaluronidase injection) ISTA Pharmaceuticals, Inc DDMAC 11/2/2005 11/3/2005
Z-LABS Progesterone Cream (Warning Letter) PDF or HTML Bio-Health DNDLC 11/9/2005 11/10/2005
Zyflo Filmtab (zileuton tablets) (Warning Letter) Critical Therapeutics, Inc. DDMAC 11/8/2005 11/9/2005
October 2005
Product/Issue Company/Individual Division Released Posted
Clinical Study (Warning Letter) Dr. Spencer Jones DSI 10/27/2005 11/2/2005
September 2005
Product/Issue Company/Individual Division Released Posted
Calcitriol Injection (Warning Letter) Nephrx DDMAC 9/29/2005 9/30/2005
Cymbalta (duloxetine) Eli Lilly DDMAC 9/9/2005 11/9/2005
Lumigan (bimatoprost) ophthalmic solution (Warning Letter) Allergan, Inc. DDMAC 9/6/2005 9/8/2005
Travatan (travoprost ophthalmic solution) Alcon Research, Ltd. DDMAC 9/22/2005 9/23/2005
August 2005
Product/Issue Company/Individual Division Released Posted
Nipent (pentostatin) for Injection (Warning Letter) SuperGen, Inc. DDMAC 8/18/2005 8/22/2005
Site Inspection (Warning Letter) Similasan AG DMPQ 8/16/2005 9/7/2005
July 2005
Product/Issue Company/Individual Division Released Posted
Domperidone (Warning Letter) Cape Drugs DNDLC 7/11/2005 8/10/2005
Fuzeon (enfuvirtide) for Injection Hoffman-La Roche, Inc. DDMAC 7/15/2005 7/18/2005
Inspection (Warning Letter) Litron Laboratories, Ltd. DSI 7/1/2005 7/12/2005
Quadramet (Samarium SM 153 Lexidronam) Injection (Warning Letter) Cytogen Corporation DDMAC 7/18/2005 7/19/2005
Site Inspection (Warning Letter) ACS Dobfar DMPQ 7/21/2005 7/28/2005
Survanta (beractant) intreacheal suspension Abbott Laboratories DDMAC 7/15/2005 7/19/2005
Tracleer (bosentan) Tablets (Warning Letter) Actelion Pharmaceuticals US, Inc. DDMAC 7/20/2005 7/26/2005
ZYVOX (linezolid) injection, tablets, and oral suspension (Warning Letter) Pfizer, Inc. DDMAC 7/20/2005 7/26/2005
June 2005
Product/Issue Company/Individual Division Released Posted
Clinical Study (Warning Letter) Clark Bishop, M.D. DSI 6/7/2005 6/22/2005
Lidoderm (Lidocaine Patch 5%) (Warning Letter) Endo Pharmaceuticals Inc. DDMAC 6/28/2005 6/29/2005
Strattera (atomoxetine HCl) Eli Lilly and Company DDMAC 6/14/2005 6/16/2005
VisionBlue (trypan blue ophthalmic solution) (Warning Letter) Dutch Ophthalmic USA DDMAC 6/28/2005 6/29/2005
May 2005
Product/Issue Company/Individual Division Released Posted
Zoloft Pfizer Pharmaceuticals DDMAC 5/6/2005 5/6/2005
Ferrlecit Watson Pharmaceuticals DDMAC 5/5/2005 5/6/2005
April 2005
Product/Issue Company/Individual Division Released Posted
CIPRO HC OTIC (Warning Letter) Alcon Laboratories, Inc. DDMAC 4/27/2005 4/28/2005
Levitra (vardenafil HCl) Tablets Bayer Pharmaceuticals, Corp. DDMAC 4/13/2005 4/15/2005
Remodulin (treprostinil sodium) Injection (Warning Letter) United Therapeutics Corporation DDMAC 4/13/2005 4/14/2005
Zyrtec (cetirizine HCl) (Warning Letter) Pfizer, Inc. DDMAC 4/13/2005 4/15/2005
March 2005
Product/Issue Company/Individual Division Released Posted
Aggrenox (aspirin/extended-release dipyridamole) Capsules Boehringer Ingelheim Pharmaceuticals, Inc. DDMAC 3/22/2005 3/23/2005
Crestor (rosuvastatin calcium) AstraZeneca Pharmaceuticals LP DDMAC 3/8/2005 3/14/2005
Tindamax (tinidazole tablets) (Warning Letter) Presutti Laboratories, Inc. DDMAC 3/30/2005 4/14/2005
February 2005
Product/Issue Company/Individual Division Released Posted
Enbrel (etanercept) (Warning Letter) Amgen DDMAC 2/18/2005 2/18/2005
Remicade Centocor DDMAC 2/11/2005 2/14/2005
Site Inspection (Warning Letter) Germiphene Corporation DMPQ 2/15/2005 3/21/2005
January 2005
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) Gene Logic DSI 1/28/2005 2/11/2005
Celebrex & Bextra Pfizer Inc. DDMAC 1/10/2005 1/12/2005
Coreg (carvedilol) Tablets (Warning Letter) GlaxoSmithKline DDMAC 1/31/2005 2/3/2005

top arrow Back to Top     back arrow Index

Date created: January 12, 2004; updated February 8, 2006

horizonal rule